Veracyte, Inc. VCYT
24.06 USD -1.86 (-7.18%)
At closeNov 11, 2026, 5:19 AM EST
24.13 +0.07 +0.29%
Pre-market · Nov 11, 5:19 AM ET
23.73 Day range 25.88
21.91 52-week range 60.91
- YTD
- -42.85%
- 1 year
- -43.60%
News
seekingalpha.com Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call…
globenewswire.com Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT) Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were…
benzinga.com Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30 Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.
benzinga.com Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40 Freedom Capital Markets analyst Keith Hinton maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $66 to $40.
businesswire.com VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
benzinga.com UBS Maintains Buy on Veracyte, Lowers Price Target to $35 UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.
defenseworld.net Veracyte (NASDAQ:VCYT) Sees Unusually-High Trading Volume – Still a Buy? Shares of Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) saw unusually-high trading volume on Friday. 1,904,920 shares traded hands during trading, an increase of 57% from the average daily volume…
zacks.com Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
prnewswire.com VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte /PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which
seekingalpha.com Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive…
prnewswire.com Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT) Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi and Korsinsky investigates into potential…
globenewswire.com VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc. VCYT's stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
benzinga.com Why Is Veracyte Stock Sinking Thursday? Veracyte (VCYT) stock tumbled 54% to a new 52-week low as weaker-than-expected Decipher Prostate test volumes overshadowed Q3 earnings beat.
benzinga.com Dow Surges 250 Points; US Weekly Jobless Claims Fall U.S. stocks mixed: Dow +0.47%, Nasdaq -1.35%, S&P 500 -0.55%. Jobless claims fell to 189,000; oil and gold rose.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.
benzinga.com Leerink Partners Downgrades Veracyte to Market Perform, Lowers Price Target to $35 Leerink Partners analyst Puneet Souda downgrades Veracyte (NASDAQ:VCYT) from Outperform to Market Perform and lowers the price target from $55 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Needham Maintains Buy on Veracyte, Lowers Price Target to $46 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $69 to $46.
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
marketbeat.com What Veracyte (VCYT) Said on Its Q3 Earnings Call Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's…
zacks.com Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.51 per share a year ago.
benzinga.com Veracyte Q3 2026 Earnings Call Transcript Veracyte (NASDAQ:VCYT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Veracyte Narrows FY2026 Sales Guidance from $590.000M-$596.000M to $590.000M-$593.000M vs $593.894M Est Veracyte (NASDAQ:VCYT) narrows FY2026 sales outlook from $590.000 million-$596.000 million to $590.000 million-$593.000 million vs $593.894 million estimate.
benzinga.com Veracyte Q3 Adj. EPS $0.51 Beats $0.41 Estimate, Sales $151.754M Beat $147.439M Estimate Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.41 by 24.39 percent. This is unchanged from the same period last year. The…
globenewswire.com Veracyte Announces Third Quarter 2026 Financial Results Grew total revenue to $151.8 million and testing revenue to $146.4 million , representing 15% year-over-year growth Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., Nov.…- benzinga.com Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment…